On August 29, 2019 Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, reported that Robert Bazemore, president and chief executive officer, will participate in the following September investor conferences (Press release, Epizyme, AUG 29, 2019, View Source [SID1234539124]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 14th Annual Biotech Conference’s "Focusing the Laser on Precision Oncology – Part 2" Company Panel on Thursday, Sept. 5, 2019 at 9:30 a.m. ET in Boston; and,
Morgan Stanley 17th Annual Global Healthcare Conference (fireside chat) on Monday, Sept. 9, 2019 at 3:40 p.m. ET in New York City.
Live webcasts will be available in the investor section of the company’s website at www.epizyme.com. The webcasts will be archived for 60 days following the presentations.